title: Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.
authors.affiliation: Department of Rheumatology, Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile.
authors.forename: Josefina
authors.initials: J
authors.lastname: Durán
authors.affiliation: Clinical Epidemiology Unit, School of Medicine, Boston University, Boston, Massachusetts, USA Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.
authors.forename: David T
authors.initials: DT
authors.lastname: Felson
mesh_terms: D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D001688:Biological Products; D006801:Humans; D008727:Methotrexate
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D008727:Methotrexate
keywords: DMARDs (biologic); Methotrexate; Rheumatoid Arthritis; Treatment